AlloVir (ALVR) (~$74MM market cap) is clinical-stage biotech centered on cell remedy to deal with viral illnesses. On 12/22/23, AlloVir paused their Section 3 research for Posoleucel after advisors concluded the research have been unlikely to fulfill their main endpoints. Alongside the announcement, the corporate introduced, “we are going to instantly shift our focus to protect our substantial remaining capital, evaluation our pipeline, and assess strategic choices.” AlloVir does have 3 further pipeline property:
About AlloVir’s Earlier Stage Virus-Particular T cell Pipeline
Grownup Kidney Transplantation
AlloVir has earlier reported the outcomes of its accomplished Section 2 randomized, placebo-controlled trial evaluating posoleucel for the remedy of BKV an infection in grownup kidney transplant sufferers. After 24 weeks of remedy, 39% of sufferers receiving posoleucel skilled a ≥1-log viral load discount, in comparison with 14% of sufferers receiving placebo.
Acute Respiratory An infection
The corporate has accomplished Half A of a randomized, placebo-controlled Section 1b/2a trial with ALVR106 in 14 stem cell or strong organ transplant sufferers. ALVR106 is an investigational allogeneic, off-the-shelf, multi-virus-specific VST remedy candidate designed to focus on illnesses brought on by human metapneumovirus (hMPV), influenza, parainfluenza virus (PIV) and respiratory syncytial virus (RSV). Knowledge has been accepted for presentation at a scientific convention within the first quarter of 2024.
Power Hepatitis B An infection
ALVR107 is an investigational allogeneic, off-the-shelf VST remedy designed to focus on hepatitis B virus (HBV)-infected cells and doubtlessly treatment sufferers with persistent HBV an infection. Preclinical and IND-enabling research help the development of ALVR107 right into a scientific proof of idea examine as a subsequent step.
A few of these could be value one thing, or not. The corporate, sadly, did not give us present money or formally announce a discount in workforce (however in case you examine LinkedIn, lots of their workers are “in search of work”). My again of the envelope math:
Somebody talked about to me we should always hope the “observe Tang” technique continues into 2024, he is not on the shareholder registry right here (but), however developing with an identical supply to what he is been throwing round, I get one thing like $0.83/share in money plus a CVR for any legacy asset proceeds. There’s a good amount of money burn danger right here since we do not have a lot steerage from administration, however the time between strategic alts bulletins and deal bulletins appears to be shortening in these damaged biotechs. A poorly thought out reverse merger is all the time a priority too, nonetheless there are some actual shareholders right here, hopefully they supply some sanity.
Disclosure: I personal shares of ALVR
